South San Francisco, United States
ALX Oncology is a publicly traded, clinical-stage immuno-oncology company established in 2015. The company's primary focus is on developing therapies that target the CD47 checkpoint pathway in the immune system to combat cancer. Their lead product candidate, evorpacept (ALX148), is a next-generation CD47 blocking therapeutic that has displayed promising clinical responses in various hematologic and solid malignancies when combined with leading anti-cancer agents. ALX Oncology is making strides in the fields of Biopharma, Biotechnology, and Healthcare.
The most recent investment in ALX Oncology amounted to $63.20 million in post-IPO equity, which took place on October 5, 2023. The investors involved in this round were not specified.
With a strong focus on innovative cancer treatments and a solid financial backing, ALX Oncology has the potential to be a game-changer in the immuno-oncology space, offering hope to cancer patients worldwide.
